Changing M3G/M6G ratios and pharmacodynamics in a cancer patient during long-term morphine treatment.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 11844638.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A cancer patient receiving long-term oral sustained-release morphine treatment and periodically presenting with unusually high plasma M3G/M6G ratios is described. We found the patient's formation of M6G more unstable and perhaps delayed compared to the formation of M3G. There is no apparent explanation for this phenomenon and the high M3G/M6G ratios had no implications for the patient's pain experience or side effects from the morphine treatment.
Medical subject headings
- Analgesics, Opioid
- Central Nervous System Stimulants
- Morphine
- Morphine Derivatives
- Pain
- Prostatic Neoplasms